IP Library Granted Patent US 7,910,691
Granted Patent B2
US 7,910,691 · App. 11/929,351 · Granted Mar 22, 2011

MN gene and protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,691
App. No.
11/929,351
Granted
Mar 22, 2011
Kind
B2
Abstract

Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed.

Claims (9)

1. A polypeptide that binds specifically to a site on MN protein to which vertebrate cells adhere in a cell adhesion assay, wherein said polypeptide when tested in vitro inhibits the adhesion of cells to MN protein and competes for binding to MN's cell adhesion site with the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128.

2. The polypeptide of claim 1 wherein said polypeptide, when in contact with a vertebrate preneoplastic or neoplastic cell that abnormally expresses MN protein, inhibits the growth of said cell.

3. The polypeptide of claim 1 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 137 and 138.

4. The polypeptide of claim 1 wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOS: 137 and 138.

5. The polypeptide of claim 1 wherein the site on the MN protein to which said vertebrate cells adhere in said cell adhesion assay is within the proteoglycan-like domain of the MN protein.

6. The polypeptide of claim 1 wherein the site on the MN protein to which said vertebrate cells adhere in said cell adhesion assay comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 10 and 97-106.

7. The polypeptide of claim 1 wherein the site on the MN protein to which said vertebrate cells adhere in said cell adhesion assay has an amino acid sequence selected from the group consisting of SEQ ID NOS: 10 and 97-106.

8. The polypeptide of claim 1 wherein said vertebrate cells are mammalian.

9. The polypeptide of claim 1 wherein said vertebrate cells are human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2018
From: INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES
To: BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES
Reel/Frame 046294/0714 →
SUBMISSION IS TO CORRECT AN ERROR MADE IN A PREVIOUSLY RECORDED DOCUMENT THAT ERRONEOUSLY AFFECTS THE IDENTIFIED APPLICATIONS/PATENTS. Recorded Jul 24, 2013
From: INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES
To: INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES
Reel/Frame 030871/0331 →